Home
About
About Anagenics
Directors and Management
Divisions
Our Divisions
Beauty
Brands
évolis®
Uspa
Investors
Investor Centre
ASX Announcements
2023
2022
2021
2020
2019
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Corporate Governance
Corporate Governance
Board Charter
Code of Conduct
Policies
Audit Committee Charter
Nomination and Remuneration Committee Charter
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
✕
2013
Home
2013
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Change in Director’s Interest – M Halasz
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Change in Director’s Interest – M Halasz
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
European Patent Allowed for Treating Vascular Occlusive Disease
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Positive Data in Midkine Antibody Study in Kidney Disease
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Appendix 4C Quarterly report
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Cellmid News
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Cellmid Signs Midkine Diagnostic Agreement
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Change in Director’s Interest – M Rogers
November 13, 2019
Published by
Tiffany McMillan
on
November 13, 2019
Categories
Change in Director’s Interest – M Halasz
1
2
3
4
5
6
Next page
